Anti-human interleukin-17A monoclonal antibody

Abstract

An anti-human IL-17A monoclonal antibody, the preparation method, and the use thereof are provided. The anti-human IL-17A monoclonal antibody can specifically bind to human IL-17A and has a good effect for inhibiting the secretion of inflammatory cytokines, such as IL-6 and the like by means of various cell lines induced by IL-17A, and can be used for preparing drugs for treating diseases involving immune-medicated inflammatory responses.

What is claimed is: 
     
       1. An isolated anti-human IL-17A monoclonal antibody comprising:
 (1) a heavy chain variable region comprising CDR1, CDR2 and CDR3, wherein the CDR1 has the amino acid sequence of SEQ ID NO: 5, the CDR2 has the amino acid sequence of SEQ ID NO: 6, and the CDR3 has the amino acid sequence of SEQ ID NO: 7; and 
 (2) a light chain variable region comprising CDR1′, CDR2′ and CDR3′, wherein the CDR1′ has the amino acid sequence of SEQ ID NO: 8, the CDR2′ has the amino acid sequence of SEQ ID NO: 9, and the CDR3′ has the amino acid sequence of SEQ ID NO: 10. 
 
     
     
       2. The anti-human IL-17A monoclonal antibody of  claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 2, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 4. 
     
     
       3. The anti-human IL-17A monoclonal antibody of  claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 12, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 14, and wherein the antibody is a humanized antibody. 
     
     
       4. The anti-human IL-17A monoclonal antibody of  claim 3 , comprising a heavy chain having the amino acid sequence of SEQ ID NO: 15, and a light chain having the amino acid sequence of SEQ ID NO: 16. 
     
     
       5. A composition, comprising the anti-human IL-17A monoclonal antibody of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
       6. An isolated polynucleotide encoding the anti-human IL-17A monoclonal antibody of  claim 1 . 
     
     
       7. The polynucleotide of  claim 6 , wherein the nucleotide sequence encoding the heavy chain variable region of the antibody comprises SEQ ID NO:1, and the nucleotide sequence encoding the light chain variable region of the antibody comprises SEQ ID NO:3. 
     
     
       8. The polynucleotide of  claim 6 , wherein the nucleotide sequence encoding the heavy chain variable region of the antibody comprises SEQ ID NO:17, and the nucleotide sequence encoding the light chain variable region of the antibody comprises SEQ ID NO:18. 
     
     
       9. The polynucleotide of  claim 6 , wherein the nucleotide sequence encoding the heavy chain variable region of the antibody comprises SEQ ID NO:11, and the nucleotide sequence encoding the light chain variable region of the antibody comprises SEQ ID NO:13. 
     
     
       10. The polynucleotide of  claim 6 , wherein the nucleotide sequence encoding the heavy chain variable region of the antibody comprises SEQ ID NO:19, and the nucleotide sequence encoding the light chain variable region of the antibody comprises SEQ ID NO:20. 
     
     
       11. An expression vector, comprising the polynucleotide of  claim 6 . 
     
     
       12. An isolated host cell, comprising the expression vector of  claim 11 . 
     
     
       13. A method of preparing an anti-human IL-17A monoclonal antibody encoded by the polynucleotide in the expression vector in the host cell of  claim 12 , comprising the steps of: a) culturing the host cell under suitable conditions to express the antibody; and b) isolating and purifying the expressed antibody.